Publications by authors named "Mark Huberman"

Claim this Profile
A
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.
Kartik Sehgal, Anushi Bulumulle, Heather Brody, Ritu R Gill, Shravanti Macherla, Mark S Huberman

Clin Lung Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III -Mutant Non-Small-Cell Lung Cancer.
Joel W Neal, Daniel B Costa, Alona Muzikansky, Joseph B Shrager, Michael Lanuti, Mark S Huberman

JCO Precis Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
Susan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R Oxnard, Mark S Huberman

Clin Cancer Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
Susan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R Oxnard, Mark S Huberman

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.
Lorena Ostios-Garcia, Jennifer Faig, Giulia C Leonardi, Anika E Adeni, Safiya J Subegdjo, Mark S Huberman

J Thorac Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
Paul A VanderLaan, Deepa Rangachari, Adnan Majid, Mihir S Parikh, Sidharta P Gangadharan, Mark S Huberman

Lung Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.
Deepa Rangachari, Xiuning Le, Meghan Shea, Mark S Huberman, Paul A VanderLaan

J Thorac Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Deepa Rangachari, Paul A VanderLaan, Meghan Shea, Xiuning Le, Mark S Huberman

J Thorac Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
Paul A VanderLaan, Deepa Rangachari, Susan M Mockus, Vanessa Spotlow, Honey V Reddi, Mark S Huberman

Lung Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma.
Helen Shields, Justin Li, Stephen Pelletier, Helen Wang, Rachel Freedman, Mark Huberman

Dis Esophagus· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.
Yuri Sheikine, Deepa Rangachari, Danielle C McDonald, Mark S Huberman, Erik S Folch

Clin Lung Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.
Antonio R Lucena-Araujo, Jason P Moran, Paul A VanderLaan, Dora Dias-Santagata, Erik Folch, Mark S Huberman

Lung Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.
Meghan Shea, Mark S Huberman, Daniel B Costa

J Thorac Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapidly fatal advanced -mutated lung cancers and the need for rapid tumor genotyping in clinical practice.
Deepa Rangachari, Lauren Drake, Mark S Huberman, Danielle C McDonald, Paul A VanderLaan

Cancer Treat Commun· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Daniel B Costa, Susan E Jorge, Jason P Moran, Jason A Freed, Jessica A Zerillo, Mark S Huberman

J Thorac Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Susan E Jorge, Sol Schulman, Jason A Freed, Paul A VanderLaan, Deepa Rangachari, Mark S Huberman

Lung Cancer· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
Xiuning Le, Jason A Freed, Paul A VanderLaan, Mark S Huberman, Deepa Rangachari

Clin Lung Cancer· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.
Deepa Rangachari, Norihiro Yamaguchi, Paul A VanderLaan, Erik Folch, Anand Mahadevan, Mark S Huberman

Lung Cancer· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
Xiuning Le, Neelam V Desai, Adnan Majid, Rebecca S Karp, Mark S Huberman

Lung Cancer· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice.
Deepa Rangachari, Paul A VanderLaan, Xiuning Le, Erik Folch, Michael S Kent, Mark S Huberman

Cancer Treat Commun· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.
Paul A Vanderlaan, Norihiro Yamaguchi, Erik Folch, David H Boucher, Michael S Kent, Mark S Huberman

Lung Cancer· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Hiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun, Natasha J Sng, Antonio R Lucena-Araujo, Mark S Huberman

Sci Transl Med· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.
Erik Folch, Norihiro Yamaguchi, Paul A VanderLaan, Olivier N Kocher, David H Boucher, Mark S Huberman

J Thorac Oncol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
Norihiro Yamaguchi, Paul A Vanderlaan, Erik Folch, David H Boucher, Hannah M Canepa, Mark S Huberman

Lung Cancer· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
Mark A Socinski, Jonathan Goldman, Iman El-Hariry, Marianna Koczywas, Vojo Vukovic, Mark Huberman

Clin Cancer Res· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis